JPRN-C000000350
Completed
Phase 2
Phase II study of Chemotherapy for Advanced or Recurrent Thymoma - Chemotherapy for Advanced Thymoma
Japanese Association for Research on the Thymus0 sites50 target enrollmentApril 1, 2006
ConditionsThymoma (excluding thymic carcinoma)
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Thymoma (excluding thymic carcinoma)
- Sponsor
- Japanese Association for Research on the Thymus
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with malignancies other than thymoma (those with CR can be included). Patients who has been treated with steroid pulse therapy within one month of the registration. Patients on oral steroid at a dose of more than 26mg every other day or 13mg everyday. Pregnant women.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Phase II study of up-front chemotherapy and neo-adjuvant short-course radiotherapy for resectable rectal carcinomaresectable rectal carcinomaMedDRA version: 15.1 Level: LLT Classification code 10038052 Term: Rectal carcinoma System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-000770-30-ITIRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO50
Completed
Phase 2
Phase II study of intensive chemotherapy in treating pediatric patients with newly diagnosed cranial nongerminomaous germ cell tumorJPRN-UMIN000002398Japanese Pediatric Brain Tumor Consortiun20
Completed
Phase 2
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22
Completed
Phase 1
Phase I / II Study of Alternating Chemotherapy with Cisplatin plus Nogitecan plus Paclitaxel (PlaTT) and Cisplatin plus Amrubicin plus Paclitaxel (PAT) for Advanced Lung Cancer PatientsAdvanced Lung CancerJPRN-UMIN000012270iigata Lung Cancer Treatment Group18
Recruiting
Phase 2
Phase II study of elental for chemotherapy induced mucositis oral and nutritional disturbanceJPRN-UMIN000009298Aizawa Hospital30